TITLE

The global cardiovascular drug market

AUTHOR(S)
Quirk, Jeremy; Maidwell, Nicola
PUB. DATE
April 2004
SOURCE
International Journal of Medical Marketing;Apr2004, Vol. 4 Issue 2, p96
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents an overview of the global cardiovascular drug market. Expectation of the growth of the value of the cardiovascular market in future; Dependence of the size and shape of the cardiovascular market on strong and often opposing forces; Definition and treatment of the cardiovascular disease in terms of individual risk factors; Dependency of a drug's success in the cardiovascular market on the ability to improve patient health.
ACCESSION #
12483820

 

Related Articles

  • CPE SERIES: MTM CONSIDERATIONS FOR ADULT PATIENTS WITH CARDIOVASCULAR DISEASE.  // Drug Topics;Oct2014, Vol. 158 Issue 10, p54 

    The article discusses motivational interviewing that pharmacists can use to engage patients in their health and lead to improved cardiovascular outcomes. Topics discussed include the definition of motivational interviewing as a patient-centered and collaborative using a directive counseling...

  • YOGA--GOOD FOR THE HEART!  // Saturday Evening Post;Sep/Oct2004, Vol. 276 Issue 5, p12 

    Deals with the health benefits of yoga to patients coping with heart disease. Information on the Hatha Yoga Cardiac Program at Cedars Sinai Medical Center in Los Angeles, California; Effect of yoga on patients with stress problems.

  • The Integrated Workout. Teta, Jade; Teta, Keoni // Townsend Letter;Dec2010, Issue 329, p89 

    The article provides information on a science-based fitness protocol called the integrated workout, which doctors can prescribe to help their patients develop health, fitness and fat loss. It says that prescribing the integrated workout involves selecting four exercises that work big muscle...

  • The Post-Statin World. Trahan, Ronald C. // Pharmaceutical Executive;Apr2003, Vol. 23 Issue 4, p76 

    Comments on the need for drug marketing firms to study the possibilities in cardiovascular treatment in order to prepare drug efficacy communication strategies for therapeutic promotions. Opportunities in metabolic syndrome studies; Metrics for the diagnosis, progression and prognosis of...

  • Under legal fire, Miles ends drug switch payments. Ukens, Carol // Drug Topics;4/25/94, Vol. 138 Issue 8, p26 

    Reports on the agreement between the attorneys-general of 11 states and Miles Inc. on the termination of Miles' reimbursement program that paid pharmacists for each patient agreeing to switch to Adalat CC. Features of the program; Reaction by Miles Inc.; Alleged violation of consumer protection...

  • Association of body mass index and outcomes after major lung resection†. Ferguson, Mark K.; Im, Hae Kyung; Watson, Sydeaka; Johnson, Elizabeth; Wigfield, Christopher H.; Vigneswaran, Wickii T. // European Journal of Cardio-Thoracic Surgery;Apr2014, Vol. 45 Issue 4, pe94 

    OBJECTIVES Obesity has been thought to predispose patients to excess morbidity after lung resection because of decreased diaphragm excursion, reduced lung volumes and relative immobility. We assessed the relationship of body mass index (BMI) to acute outcomes after major lung resection. METHODS...

  • The Significance of the Psychosocial Factors Influence in Pathogenesis of Cardiovascular Disease. Masic, Izet; Alajbegovic, Jasmin // International Journal of Preventive Medicine;Nov2013, Vol. 4 Issue 11, p1323 

    Background: Cardiovascular diseases (CVD) are the leading cause of death in the world today. Risk factors are those factors that influence the development of CVD. Risk factors can be divided into materialistic (genetic predisposition, smoking, alcohol) and non-materialistic (psychosocial...

  • Heart Disease Management. Freed, Stephen; Mannen, Jared // Chain Drug Review;9/24/2012, Vol. 34 Issue 16, p134 

    The article focuses on the involvement of community pharmacists in patient care. The authors mention that numerous studies have demonstrated that interventions by community pharmacists can improve outcomes in patients with cardiovascular disease. They note the Asheville Project which illustrates...

  • Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Schnell, Oliver; Standl, Eberhard; Catrinoiu, Doina; Genovese, Stefano; Lalic, Nebojsa; Skra, Jan; Valensi, Paul; Ceriello, Antonio // Cardiovascular Diabetology;2/18/2016, Vol. 15, p1 

    The 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held during the annual meeting on 30 October 2015 in Munich. This summit was organized in light of recently published and numerous ongoing CVOTs on diabetes, which have...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics